Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Vasculitis 1Neoplasms 1Lupus Erythematosus, Systemic 1Glomerulonephritis 1COVID-19 1

Interventions

Nivolumab 2sotrovimab 1gusacitinib 1ciclesonide 1cabozantinib 1anifrolumab 1Standard of Care 1Specimen Handling 1Procalcitonin 1Practice Guidelines as Topic 1Platinum Compounds 1Niclosamide 1Methods 1Ipilimumab 1Interviews as Topic 1Immune Checkpoint Inhibitors 1High-Intensity Interval Training 1Exercise 1Educational Status 1Early Intervention, Educational 1Cholecalciferol 1CTLA-4 Antigen 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lupus Erythematosus, Systemic × ciclesonide × Clear all
NCT04870333 2025-06-20

PROTECT-V

Cambridge University Hospitals NHS Foundation Trust

Phase 2/3 Completed
2,240 enrolled

COVID-19, Glomerulonephritis, Lupus Erythematosus, Systemic, Neoplasms, Vasculitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡